A clinical trial to study the anti-inflammatory effect of Virecanakarma in Ki?ibhaku??ha (Psoriasis)
Not Applicable
- Conditions
- Health Condition 1: L409- Psoriasis, unspecified
- Registration Number
- CTRI/2023/07/054849
- Lead Sponsor
- S.V. Ayurvedic college and hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of age group 18-65 years.
Patients presenting with the signs and symptoms of Kit?ibha.
Patients presenting with the signs and symptoms of Psoriasis.
Patients who are eligible for Virecana.
Exclusion Criteria
Patients below the age of 18 and above the age of 65 years.
Patients with Diabetes and Hypertension.
Patients with TB, HIV, Cancer and other major systemic diseases.
Patients who are not eligible for Virecana.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To prove the Anti-inflammatory effect of Virecanakarma by comparing the efficacies of Kalya¯n?aka gud?a & Ma¯n?ibhadra gud?a by evaluation of Inflammatory markers <br/ ><br>Timepoint: At baseline, aftr completion of treatment (11th-18th day), 7weeks <br/ ><br>
- Secondary Outcome Measures
Name Time Method To prove the Anti-inflammatory effect of Virecanakarma by comparing the efficacies of Kalya¯n?aka gud?a & Ma¯n?ibhadra gud?a by evaluation of Inflammatory markersTimepoint: At baseline, after completion of treatment( 11th-18th day), aftr 7weeks